TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics
FORT WORTH, Texas, Nov. 03, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced a collaboration with Aptar Pharma, a global leader in drug delivery and active material science solutions and services, aimed at developing and testing the administration of dry powder vaccines utilizing TFF Pharmaceutical’s Thin Film Freezing technology and Aptar Pharma’s proprietary intranasal Unidose (UDS) Powder Nasal Spray System.
- The development of an effective intranasal vaccine has numerous potential advantages over conventional, subcutaneous or intramuscular-based delivery.
- These aspects of nasal delivery could expand vaccine availability to larger populations in regions and countries with limited refrigeration infrastructure.
- During the Vaccines Summit-2022, which took place from October 11 to 13, 2022 in Washington DC, U.S., Aptar Pharma presented research findings from their collaboration with TFF Pharmaceuticals.
- Intranasal dry powder vaccines could be a true game changer for people around the world.